Abstract

The discovery and development of new pharmaceutical agents has become increasingly complex, time-consuming, and expensive, with traditional approaches requiring over a decade and billions of dollars to bring a single drug to market. Computational drug design has emerged as a transformative approach to address these challenges by accelerating the identification, optimization, and validation of drug candidates through sophisticated in silico methodologies. This article examines the fundamental principles, methodologies, and applications of computational drug design in contemporary pharmacological research. Key approaches including structure-based drug design, ligand-based methods, molecular modeling, virtual screening, and in silico optimization are reviewed in the context of their theoretical foundations and practical implementations. The integration of computational strategies with experimental and translational pharmacology has demonstrated substantial improvements in efficiency, accuracy, and success rates across multiple stages of drug discovery, from initial target identification through preclinical optimization. These methods have enabled researchers to explore vast chemical spaces, predict molecular interactions, assess pharmacokinetic properties, and prioritize promising candidates before resource-intensive synthesis and biological testing. Despite inherent limitations related to model accuracy, validation requirements, and regulatory considerations, computational drug design continues to evolve through advances in artificial intelligence, machine learning, and high-performance computing. The future of pharmacological research lies in the seamless integration of computational predictions with experimental validation, personalized medicine approaches, and real-world clinical applications, promising more efficient pathways to therapeutic innovation.